Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy.
Daniel LaxarEva SchadenMarion WiegeleKonrad HötzeneckerStefan SchwarzJohannes GratzPublished in: Journal of clinical medicine (2023)
Of the 17 patients who received 50 doses of rFVIIa, bleeding ceased in four patients without surgical intervention. Only 14% of rFVIIa administrations resulted in hemorrhage control, whereas 71% of patients required revision surgery for bleeding control. Overall, 84% of all recommended preconditions were fulfilled; however, fulfillment was not associated with rFVIIa efficacy. The incidence of thromboembolic events within five days of rFVIIa administration was comparable to cohorts not receiving rFVIIa.
Keyphrases
- end stage renal disease
- patients undergoing
- atrial fibrillation
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- randomized controlled trial
- stem cells
- prognostic factors
- intensive care unit
- total knee arthroplasty
- patient reported outcomes
- coronary artery disease
- percutaneous coronary intervention
- acute coronary syndrome
- cell therapy
- patient reported
- cardiac surgery